Clinical trial
A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (Velcade) in Patients With Multiple Myeloma in First or Second Relapse.
NCT01910987 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (Velcade) in Patients With Multiple Myeloma in First or Second Relapse.
- Lead sponsor
- Janssen-Cilag International NV
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2013
- Completion date
- February 29, 2016
- Enrollment
- 80 (actual)
- Sites
- 54
Conditions
As the registry lists them; a condition with its own page is linked.